Kybella® (Chin Fat Reduction)
What is KYBELLA®
Kybella is a revolutionary product designed to melt away that stubborn fat under your chin known as submental fullness or “double chin.” As the only FDA-approved injectable solution, it uses synthetic deoxycholic acid which is a molecule that occurs naturally in the body to destroy fat cells and improve your profile.
KYBELLA® is for you if…
- You are self-conscious about your double chin.
- You still have fat under your chin despite a healthy diet and exercise.
- You do not want to have surgery.
- Your double chin makes you look older or more unhealthy than you actually are.
Kybella® uses a synthetic deoxycholic acid which is a molecule that occurs naturally in the body and aids in the breakdown and absorption of dietary fat.
A typical treatment takes about 20 minutes, so you can get in, get out, and get on with your day while the fat melts away.
- No Surgery Required
Kybella® uses a simple procedure that requires up to 6 treatments. During each treatment, Kybella® is used in a series of small injections under the chin, which means no surgery is required.
- Lifelong results
When a treatment is done, Kybella® destroys those stubborn fat cells and prevents them from storing or accumulating more fat. This means results should be permanent regardless of future weight gain.
Let us help!
Our board certified aestheticians can help you reduce the appearance of moderate to severe submental fullness, commonly known as a double chin, and restore that thin healthy look. You can see results in as little as one treatment but may require additional treatments. Give us a call to set up a consultation. Find out if Kybella should be a part of your cosmetic plan!
KYBELLA® (deoxycholic acid) injection 10 mg/mL
Indication and Important Safety Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see KYBELLA® full prescribing information.